GlassScriptPhysician profile
Michael L Cohan
NPI 1144271297
$5,205.75
in general payments reported to CMS, 2019-2025
18 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $376 · 2021: $646 · 2022: $934 · 2023: $1,118 · 2024: $732 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.52 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,310.81 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,052.51 | 2019-2025 | Tavneos, Parsabiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $550.58 | 2021-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $410.19 | 2022-2023 | Lupkynis |
| Abbvie INC. | $400.00 | 2019 | |
| Ardelyx, INC. | $232.82 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Novartis Pharmaceuticals Corporation | $192.64 | 2023-2025 | |
| Travere Therapeutics, INC. | $188.21 | 2022-2023 | |
| Akebia Therapeutics INC | $180.57 | 2019-2025 | Vafseo |
| Horizon Therapeutics Plc | $138.20 | 2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $105.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.27 | 2019 | |
| Fresenius USA Marketing, INC. | $75.96 | 2019-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $70.24 | 2024-2025 | |
| Novo Nordisk INC | $55.99 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $52.91 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $50.84 | 2021-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $45.59 | 2024-2025 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.